Everest Medicines Announces Participation in September Investor Conferences

SHANGHAI, China – August 25, 2025 – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Financial Officer will be participating in person at investor conferences in New York City. 

Date: Monday September 8, 2025

Format: Fireside chat and 1x1 meetings

Time: 5:35 p.m. ET

Location: New York, NY

Date: Wednesday, September 10, 2025

Format: In-person presentation and 1x1 meetings

Time: 8:00 a.m. ET

Location: New York, NY

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. 

For more information, please visit its website at www.everestmedicines.com.

Investor Relations

Irina Koffler

LifeSci Advisors

Tel: (917) 734-7387

ikoffler@lifesciadvisors.com